B-cell receptor epitope on Human papillomavirus L1 virus-like particle (HPV L1 VLP B-cell epitope)

B-cell receptor epitopes on Human papillomavirus L1 virus-like particles are conformational sites located on the major capsid protein (L1) of HPV VLPs. These epitopes are key antigenic domains targeted by neutralizing antibodies and are the principal immune determinants exploited in licensed prophylactic HPV vaccines[2][5][6]. The L1 protein self-assembles into pentameric capsomeres that further assemble into VLPs, visually and antigenically mimicking the native virus but lacking viral genome[1][3][4][6]. B-cell activation is facilitated by the highly multivalent, repetitive structure of VLPs that enables efficient cross-linking of B-cell receptors, inducing robust, long-lived antibody responses[3][6]. Neutralizing antibody formation against these epitopes effectively prevents initial HPV infection and disease progression[5][6]. Structural studies have mapped key amino acid residues forming discontinuous but conformationally dependent neutralizing epitopes, underlining the importance of the L1 surface's integrity for vaccine efficacy[5]. No significant safety concerns are associated with these epitopes in clinical vaccine use. No small molecule drugs directly target these epitopes; interaction is limited to vaccines and monoclonal antibodies. No direct genomic or proteomic biomarkers are routinely used for patient selection beyond serology.

Other names

HPV L1 VLP B-cell epitopeHPV L1 neutralizing epitopeHPV L1 major capsid B-cell epitopeHuman papillomavirus L1 VLP B-cell epitopeL1 conformational epitope

Induction of neutralizing antibody via B-cell activation; Activation of classical complement pathway (via IgM); Prevention of HPV infection by blocking virus-cell attachment and entry.